TrumpRx Threatens Ro's Pricing Advantage
Ro vs TrumpRx
TrumpRx turns GLP-1 access from a differentiated retail offer into a near identical checkout flow, which means Ro can no longer win mainly by finding cheaper drug supply. Once federal pricing drives branded injectables to about $350 per month, patients can get a prescription from a primary care doctor and buy through the same manufacturer pharmacy rails that Ro already uses, leaving Ro to justify its extra subscription with labs, titration, and coaching instead of price alone.
-
Ro's earlier edge came from packaging a messy process into one app. It handled intake, clinician review, insurance routing, compounded supply, labs, and fulfillment, and that convenience supported high GLP-1 spend as Ro's annualized revenue rose from $360M in 2023 to $598M in 2024.
-
That edge was already narrowing before TrumpRx. After compounded GLP-1s came under pressure in early 2025, Ro and Hims shifted toward LillyDirect and NovoCare, so much of the value moved from proprietary supply to owning the consumer relationship on top of manufacturer fulfillment.
-
The next battleground is employer and payer obesity management, where buyers pay for lower total cost, better adherence, and measurable outcomes, not just easy access. That favors companies like Virta and Omada, and pushes Ro toward proving its care model saves money beyond the drug itself.
Going forward, the winners in GLP-1 telehealth will look less like online pharmacies and more like obesity care operators. If low drug prices become the market standard, Ro's growth will come from turning its care stack into a reimbursable service for employers, plans, and drug makers, where retention and outcomes matter more than markup.